Sign up to save your podcasts
Or
Share Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis
In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.
Featured Articles:
- MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
- Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
- Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases
View all episodes
By American Society of Hematology
4.1
4848 ratings
In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.
Featured Articles:
- MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
- Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
- Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases
More shows like Blood Podcast
View all
JAMA Editors' Summary
129 Listeners
Hematologic Oncology Update
71 Listeners
NEJM This Week
319 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
489 Listeners
Mayo Clinic Talks
273 Listeners
VJHemOnc Podcast
2 Listeners
Annals On Call Podcast
186 Listeners
The Curious Clinicians
362 Listeners
The BSH Guidelines Official Podcast
3 Listeners
EHA Unplugged
2 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
165 Listeners
Blood Cancer Talks
48 Listeners
HemeTalks: Conversations in Hematology Education
1 Listeners